- Report
- September 2026
- 194 Pages
Global
From €3153EUR$3,545USD£2,707GBP
€3503EUR$3,939USD£3,008GBP
- Report
- February 2026
- 250 Pages
Global
From €3993EUR$4,490USD£3,428GBP
- Report
- July 2026
- 200 Pages
Global
From €7106EUR$7,990USD£6,101GBP
- Report
- January 2026
- 280 Pages
Global
From €2668EUR$3,000USD£2,291GBP
- Report
- May 2026
- 100 Pages
Global
From €2400EUR$2,699USD£2,061GBP
- Report
- May 2026
- 150 Pages
Global
From €2480EUR$2,789USD£2,129GBP
- Report
- August 2025
- 194 Pages
Global
From €3153EUR$3,545USD£2,707GBP
€3503EUR$3,939USD£3,008GBP
- Report
- May 2024
- 132 Pages
Global
From €2667EUR$2,999USD£2,290GBP
€3557EUR$3,999USD£3,053GBP
- Report
- May 2024
- 131 Pages
Global
From €2667EUR$2,999USD£2,290GBP
€3557EUR$3,999USD£3,053GBP
- Report
- October 2023
- 145 Pages
Global
From €2802EUR$3,150USD£2,405GBP
- Report
- August 2024
- 80 Pages
Japan
From €3113EUR$3,500USD£2,672GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2668EUR$3,000USD£2,291GBP
- Report
- February 2024
- 360 Pages
Global
From €7071EUR$7,950USD£6,070GBP
- Report
- May 2024
- 132 Pages
Global
From €2667EUR$2,999USD£2,290GBP
€3557EUR$3,999USD£3,053GBP
- Report
- December 2023
- 140 Pages
Global
From €3958EUR$4,450USD£3,398GBP
- Report
- April 2025
- 137 Pages
Asia Pacific
From €3068EUR$3,450USD£2,634GBP
- Report
- April 2025
- 136 Pages
Middle East, Africa
From €3068EUR$3,450USD£2,634GBP
- Report
- July 2024
- 150 Pages
Global
From €3958EUR$4,450USD£3,398GBP
- Report
- November 2020
- 199 Pages
Global
€4002EUR$4,500USD£3,436GBP
- Report
- September 2026
- 50 Pages
Global
From €2357EUR$2,650USD£2,023GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more